Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 37 EP30 | DOI: 10.1530/endoabs.37.EP30

ECE2015 Eposter Presentations Adrenal cortex (94 abstracts)

Asymmetric dimethylarginine level and markers of atherosclerosis in Cushing's syndrome

Cemile Ozsurekci 1 , Mujde Akturk 1 , Cigdem Ozkan 1 , Ozlem Gulbahar 2 , Alev Altinova 1 , Muhittin Yalcin 1 , Emre Arslan 1 & Fusun Toruner 1

1Department of Endocrinology, Faculty of Medicine, Gazi University, Ankara, Turkey; 2Department of Biochemistry, Faculty of Medicine, Gazi University, Ankara, Turkey.

Objective: Cushing’s syndrome (CS) is related to diabetes mellitus, dyslipidaemia, hypertension, and obesity, which lead to cardiovascular disease (CVD). CVD is the major cause of mortality and morbidity in CS. The aim of our study was to investigate CVD risk markers, such as asymmetric dimethylarginine (ADMA), lipoprotein-associated phospholipase A2 (Lp-PLA2), highly sensitive C-reactive protein (hsCRP), homocysteine, lipid levels, ankle-brachial index (ABI), and carotid intima–media thickness (CIMT) in CS.

Methods: Our study included 27 patients with active CS and age, sex, BMI, and co-morbid diseases matched 27 control patients.

Results: Plasma ADMA levels were significantly lower in CS compared to the control group (P=0.013). Total cholesterol, LDL cholesterol, HDL cholesterol, apo A1, and apo B levels were higher in patients with CS than the control group (P<0.05). We did not find any statistically significant difference in hsCRP, Lp-PLA2, and homocysteine levels, CIMT and ABI measurements between CS and control groups (P>0.05).

Conclusion: Our results suggest that CVD in CS may occur primarily due to comorbid diseases with CS. We found that ADMA levels were lower in CS than co-morbid diseases matched control group, which should be further investigated.

Disclosure: This project was supported by IMSED (Internal Medicine Postgraduate Education Association).

Article tools

My recent searches

No recent searches.